Dr. Daniel Botelho Costa M.D.
Hematologist-Oncologist | Hematology & Oncology
330 Brookline Ave Shapiro 9 Boston MA, 02215Rating
5/5
About
Dr. Daniel Costa is a hematologist oncologist practicing in Boston, MA. Dr. Costa specializes in the diagnosis, treatment and prevention of blood diseases such as anemia, hemophilia, sickle-cell disease, leukemia and lymphoma. Hematologist Oncologists are also trained in the study of cancer and its attack on other organs.
Education and Training
Faculdade De Medicina (Sao Paulo, Brazil) MD 2000
Faculty Of Med Of Ribeirao Preto University Of Sao Paulo 2000
Centro Universit·rio S„o Camilo 2000
Board Certification
Internal MedicineAmerican Board of Internal MedicineABIM
Provider Details
Expert Publications
Data provided by the National Library of Medicine- Recurrent infections in multiple myeloma.
- Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.
- Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
- To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
- Response of intracranial metastases to epidermal growth factor receptor tyrosine
- Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population.
- Gefitinib plus docetaxel in non-small-cell lung cancer.
- Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
- Polymorphism of the CYP1A1*2A gene and susceptibility to lung cancer in a Brazilian population.
- Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR
- Molecular testing in lung cancer: the time is now.
- Serum concentrations of Erlotinib at a dose of 25 mg daily.
- KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma.
- CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.
Clinical Trials
Treatments
- Lung Cancer
Dr. Daniel Botelho Costa M.D.'s Practice location
Practice At 330 Brookline Ave Shapiro 9
330 Brookline Ave Shapiro 9 -Boston, MA 02215Get Direction
Dr. Daniel Botelho Costa M.D.'s reviews
Write ReviewPatient Experience with Dr. Costa
Recommended Articles
- Multiple Myeloma: What is Autotransplantation?
During a stem cell transplantation or autotransplantation, the patient receives high chemotherapy dosage which is sometimes done to the entire body to get rid of the cells that are in the bone marrow (including the myeloma cells). Afterwards, the patient receives new stem cells to form...
![]()
Promising Results for Hodgkin Patients Using This TherapyResearcher Dr. Bradford S. Hoppe and his colleagues at the University of Florida College of Medicine have recently found that the addition of proton therapy to first-line chemotherapy regimens may improve outcomes for patients with Hodgkin lymphoma.Lymphoma is classically treated with both...
![]()
Life Lessons After Multiple Misdiagnoses of Lymphoma28-year-old Jessica DeCristofaro had been coughing persistently and she was told by her doctor that it was a result of allergies. She even took medication for her supposed allergies over the course of two years. When the medication failed to improve her persistent cough, another doctor diagnosed her...
![]()
Bringing Chronic Lymphocytic Leukemia Patients and Their Doctors Together via SurveyWhile patients may entirely admire and respect their doctors, sometimes they simply do not agree with the course of action they are proposing. While this may not be a big deal for a visit about a cold or something minimal, it can be life-altering for those with chronic conditions. That is why a...
![]()
Treatment Update for Hodgkin LymphomaOver time, research has uncovered ways of treating Hodgkin lymphoma (HL) to produce an 80% to 90% cure rate. For the remaining 10% to 20% who are either resistant to the primary treatment or have relapsed, their cancer can still be fatal.The standard care for those not yet cured has been a two-step...
![]()
New Diagnostic Tool Approved for LymphomaA new diagnostic tool has been approved by the U.S. Food and Drug Administration (FDA) to help researchers identify leukemia and lymphoma cells by using a technique known as flow cytometry. A flow cytometry test for non-Hodgkin’s lymphoma (NHL) can help determine whether normal or abnormal DNA is...
Nearby Providers
![]()
Dr. YongLi Ji M.D. , PH.D.55 Fruit St Boston MA 02114![]()
Dr. Bruno Bastos M.D.44 Binney St Boston MA 02115![]()
Dr. Gary M. Strauss M.D.18 Acron Road Brookline Massachusetts 2445![]()
Prabhsimranjot Singh MD17 Faxon St Newton Massachusetts 02458![]()
Dr. Folefac Edmund M.D.79-81 Highland Ave. Salem MA 01970![]()
Dr. Susan Tinsley Schumer Other2014 Washington Street Newton Lower Falls MA 02462
Nearest Hospitals
BRIGHAM AND WOMEN'S HOSPITALl
75 FRANCIS STREET BOSTON MA 2115BOSTON CHILDREN'S HOSPITALl
300 LONGWOOD AVENUE BOSTON MA 2115